BACKGROUND: Voriconazole is a triazole antifungal medication used for prophylaxis or to treat invasive fungal infections. Inflammation of the periosteum resulting in skeletal pain, known as periostitis, is a reported side effect of long-term voriconazole therapy. The trifluorinated molecular structure of voriconazole suggests a possible link between excess fluoride and periostitis, as elevated blood fluoride has been reported among patients with periostitis who received voriconazole. METHODS: Two hundred sixty-four patients from Michigan were impacted by the multistate outbreak of fungal infections as a result of contaminated methylprednisolone injections. A retrospective study was conducted among 195 patients who received voriconazole therapy at St Joseph Mercy Hospital during this outbreak. Twenty-eight patients who received both bone scan and plasma fluoride measurements for skeletal pain were included in the statistical analyses. Increased tracer uptake on bone scan was considered positive for periostitis. The primary outcome measure was the correlation between plasma fluoride and bone scan results. RESULTS: Blood fluoride (P < .001), alkaline phosphatase (P = .020), daily voriconazole dose (P < .001), and cumulative voriconazole dose (P = .027) were significantly elevated in patients who had periostitis compared with those who did not. Discontinuation or dose reduction of voriconazole resulted in improvement of pain in 89% of patients. CONCLUSIONS: High plasma fluoride levels coupled with skeletal pain among patients who are on long-term voriconazole therapy is highly suggestive of periostitis. Initial measurement of fluoride may be considered when bone scan is not readily available. Early detection should be sought, as discontinuation of voriconazole is effective at reversing the disease.
BACKGROUND:Voriconazole is a triazole antifungal medication used for prophylaxis or to treat invasive fungal infections. Inflammation of the periosteum resulting in skeletal pain, known as periostitis, is a reported side effect of long-term voriconazole therapy. The trifluorinated molecular structure of voriconazole suggests a possible link between excess fluoride and periostitis, as elevated blood fluoride has been reported among patients with periostitis who received voriconazole. METHODS: Two hundred sixty-four patients from Michigan were impacted by the multistate outbreak of fungal infections as a result of contaminated methylprednisolone injections. A retrospective study was conducted among 195 patients who received voriconazole therapy at St Joseph Mercy Hospital during this outbreak. Twenty-eight patients who received both bone scan and plasma fluoride measurements for skeletal pain were included in the statistical analyses. Increased tracer uptake on bone scan was considered positive for periostitis. The primary outcome measure was the correlation between plasma fluoride and bone scan results. RESULTS: Blood fluoride (P < .001), alkaline phosphatase (P = .020), daily voriconazole dose (P < .001), and cumulative voriconazole dose (P = .027) were significantly elevated in patients who had periostitis compared with those who did not. Discontinuation or dose reduction of voriconazole resulted in improvement of pain in 89% of patients. CONCLUSIONS: High plasma fluoride levels coupled with skeletal pain among patients who are on long-term voriconazole therapy is highly suggestive of periostitis. Initial measurement of fluoride may be considered when bone scan is not readily available. Early detection should be sought, as discontinuation of voriconazole is effective at reversing the disease.
Authors: Elizabeth Gorski; John S Esterly; Michael Postelnick; Steven Trifilio; Michael Fotis; Marc H Scheetz Journal: Antimicrob Agents Chemother Date: 2010-10-25 Impact factor: 5.191
Authors: Robert A Wermers; Kay Cooper; Raymund R Razonable; Paul J Deziel; Gary M Whitford; Walter K Kremers; Thomas P Moyer Journal: Clin Infect Dis Date: 2011-01-16 Impact factor: 9.079
Authors: T F Wang; T Wang; R Altman; P Eshaghian; J P Lynch; D J Ross; J A Belperio; S S Weigt; R Saggar; A Gregson; B Kubak; R Saggar Journal: Am J Transplant Date: 2009-10-21 Impact factor: 8.086
Authors: Nathan P Wiederhold; Gennethel J Pennick; Sheryl A Dorsey; Wieslaw Furmaga; James S Lewis; Thomas F Patterson; Deanna A Sutton; Annette W Fothergill Journal: Antimicrob Agents Chemother Date: 2013-11-04 Impact factor: 5.191
Authors: Joud Hajjar; Alejandro Restrepo; Heta Javeri; Nathan P Wiederhold; Alexander M Papanastassiou; Thomas F Patterson Journal: J Clin Immunol Date: 2017-07-11 Impact factor: 8.317
Authors: Kahtonna C Allen; Carlos J Sanchez; Krista L Niece; Joseph C Wenke; Kevin S Akers Journal: Antimicrob Agents Chemother Date: 2015-08-31 Impact factor: 5.191
Authors: Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett Journal: Clin Infect Dis Date: 2016-06-29 Impact factor: 9.079